Evidence map›Paper›PMID 41133967›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Sequential Tumor Microenvironment Reprogramming by Nanoplatform Potentiates Sonodynamic-Chemodynamic Therapy and Immune Checkpoint Blockade in Breast Cancer.

Yang Yu, Zheming Song, Anni Zhu, Jingchao Li, Rujia Fan, Bing Xiao

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yang YuDepartment of Breast Surgery, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Henan University People's Hospital, Zhengzhou, Henan, 450003, China.
Zheming SongState Key Laboratory of Advanced Fiber Materials, College of Biological Science and Medical Engineering, Donghua University, Shanghai, 201620, China.
Anni ZhuState Key Laboratory of Advanced Fiber Materials, College of Biological Science and Medical Engineering, Donghua University, Shanghai, 201620, China.
Jingchao LiState Key Laboratory of Advanced Fiber Materials, College of Biological Science and Medical Engineering, Donghua University, Shanghai, 201620, China.ORCID https://orcid.org/0000-0002-8994-3202
Rujia FanDepartment of Obstetrics and Gynecology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Henan University People's Hospital, Zhengzhou, Henan, 450003, China.
Bing XiaoDepartment of Radiology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, 310016, China.

Funding

Donghua University 2024 Cultivation Project of Discipline InnovationNational Natural Science Foundation of China 52203194Science and Technology Commission of Shanghai Municipality 20DZ2254900
6 · The paper itself

Abstract

The complex tumor microenvironment (TME) remains a major barrier to effective breast cancer therapy. A modular nanoplatform capable of sequentially reprogramming the TME through cascade actions and responsive therapeutic functions is developed to enhance breast cancer immunotherapy. A hybrid nanoparticle (MCC) containing manganese dioxide (MnO

Indexed as

Immune Checkpoint InhibitorsMammary Neoplasms, ExperimentalNanoparticle Drug Delivery SystemNanoparticlesTumor MicroenvironmentAnimalsB7-H1 AntigenCell Line, TumorChlorophyllidesCombined Modality TherapyDrug Resistance, NeoplasmFemaleGlutathioneImmunotherapyManganese CompoundsMiceB7-H1 Antigencalcium peroxideChlorophyllidesGlutathioneImmune Checkpoint InhibitorsManganese Compoundsmanganese dioxideNanoparticle Drug Delivery SystemOxidesPeroxidesphytochlorinRadiation-Sensitizing Agentsbreast cancerimmunotherapysonodynamic therapystimulus‐responsive nanoparticlestumor microenvironment

Identifiers

PMID41133967
PMCPMC12767116

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.